Though we suspect that altered Th17 cell trafficking and function play a role in reduced disease in WIN 18,446-treated Mdr1a−/− mice, we did not observe changes in serum IL17F or IL17A associated with WIN 18,446 treatment or colitis severity. The gene discussed is IL17A; the disease is colitis.